Our company in brief

Modus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe.

Find out more

Overview

Modus Therapeutics – A Swedish drug development company in clinical phase focused on normalizing the lives for patients with Sickle Cell Disease (SCD).

Our Leadership

Modus Therapeutics has a strong Board of Directors and an experienced leadership team. This in combination with external expertise a strong team with experience in taking drugs to the market.

Investors

Modus Therapeutics is predominantly owned by KDev Investments AB, part of Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital. Other larger owners are The Foundation for Baltic and European Studies (Östersjöstiftelsen) and Praktikerinvest PE AB.